drugset
drugset / Trial / NCT05024812

Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05024812 ↗

Phase 1/2 Unknown 64 enrolled The First Affiliated Hospital of Zhengzhou University
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open-label, multicenter, single arm phase Ⅰb/Ⅱ clinical study aims to explore the efficacy and safety of fruquintinib combined with toripalimab and SOX regimen in the first-line treatment of unresectable advanced metastatic gastric or gastroesophageal junction adenocarcinoma.

Timeline

Start
2022-06-01
Primary completion
2023-08
Completion
2025-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 3 mg Oral
Subject Fruquintinib Small molecule 4 mg Oral
Subject Fruquintinib Small molecule 5 mg Oral
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background S-1 Small molecule 40 mg —
Background S-1 Small molecule 60 mg —

Indications

gastric cancer